Pinned Tweet
SUPINE mini-PNL for HORSESHOE KIDNEY 👍👍 with our chief of urology @hrizaaydin in @trabzonkeah. Many thanks again to @ytanidir and @MarmaraUroloji for sharing their knowledge with us 🙋♂️
Fatih Bıçaklıoğlu retweeted
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112
@UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
Fatih Bıçaklıoğlu retweeted
The American Cancer Society just updated its prostate cancer screening guidelines for the first time since 2010:
🔸Ages 50–69 (Average Risk): Should receive a PSA blood test every 2 years
🔸 Age 45+ (Black men & strong family history): Should receive annual PSA screenings
New evidence confirms routine PSA testing saves lives and catches cancer earlier. Talk with your doctor about what’s right for you. 🩺
pressroom.cancer.org/prostat…
#ProstateCancer #MensHealth #PreventiveCare #USCUrology
Fatih Bıçaklıoğlu retweeted
We should move beyond the Phoenix criterion (PSA nadir + 2) for defining recurrence following prostate radiotherapy.
When using the "nadir + 2" threshold, 40% of patients are found to have metastases upon PSMA-PET imaging.
By adopting "nadir + 1" as the new criterion, we could potentially cure nearly 62% of patients.
What happens if we compare prostatectomy versus radiotherapy for prostate cancer using this new cutoff value?
#EMUC26
Fatih Bıçaklıoğlu retweeted
Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer.
PSMA PET-detected nodal disease should not automatically exclude surgery; selection should weigh nodal burden, location, local extent, biology, and resectability. #ProstateCancer #AuthorCommentary on UroToday > bit.ly/4AYNG8R @GGandaglia @Leo__Quarta @Albert0Briganti @SanRaffaeleMI
Fatih Bıçaklıoğlu retweeted
Has decades of laparoscopic and robotic training left surgeons less confident converting to open surgery? GSN senior medical adviser Frederick L. Greene, MD, calls it "surgical agoraphobia" — and says training programs need to address it.
f.mtr.cool/qiuhfvf0tt
#GeneralSurgery #SurgicalEducation
Fatih Bıçaklıoğlu retweeted
⚡️ pCR rates of 55–57% with perioperative EV + pembrolizumab in MIBC are real. But clinical complete response is not a reliable surrogate for pathologic clearance.
52% of patients with endoscopic cCR still harbor residual tumor at cystectomy. ctDNA misses up to 1 in 5 cases of residual disease.
Bladder preservation is achievable in selected patients — but rigorous prospective validation is still needed before deferring cystectomy.
auanews.net/issues/articles/…
#BladderCancer
Fatih Bıçaklıoğlu retweeted
Routine screening for asymptomatic bacteriuria is not needed!!! SR and MA.
Fatih Bıçaklıoğlu retweeted
In a 10-yr follow-up of a randomized trial, Retzius-sparing RARP (better early continence) showed worse long-term cancer control than the anterior approach — 2.64x higher progression risk after adjustment. Post-hoc, hypothesis-generating. free link:authors.elsevier.com/a/1njm6…
Fatih Bıçaklıoğlu retweeted
Another IAU endorsed endourology workshop focusing on "Supermini-PNL" in stone management.All aspects will be discussed interactively by the experts with presentations and live surgery by the master Prof G.Zeng. IAU based educational activities will continue with full force..
Fatih Bıçaklıoğlu retweeted
#PURABOND -novel agent to provide fast, reliable hemostasis ⬇️ post-op bleeding, dysuria. Faster healing. Helping urologists & patients SLEEP BETTER after #BPH surgery. It’s 2026 >dependable hemostasis should be standard & enhanced mucosal resurfacing must be our goal. #EAU26
Fatih Bıçaklıoğlu retweeted
🧠 EAU 2026: What’s New in Prostate Cancer Care?
📍 Practice-changing updates every clinician should know
🔹 1. Risk Stratification Reboot
🧭 Intermediate BCR risk now split into favourable vs unfavourable
→ Alters adjuvant therapy decisions & follow-up intensity
🔹 2. Imaging Gets Smarter
🧠 PSMA-PET/CT now recommended for staging intermediate-risk PCa
🧠 MRI-first endorsed for screening & biopsy targeting
→ Earlier, more accurate staging becomes standard
🔹 3. Biopsy Strategy Updated
💉 Transperineal biopsy preferred over transrectal
→ Safer, cleaner, more precise sampling
📊 New flowchart for biopsy & imaging in BCR
🔹 4. Systemic Therapy in mHSPC
💊 Triplet therapy (ADT + docetaxel + ARPI) now formally recommended
💊 ADT + ARPI preferred in low-volume metachronous mHSPC
→ Intensified systemic care, MDT discussion now mandatory
🔹 5. CRPC & Neuroendocrine PCa
🧬 Tailored sequencing after ARPI/chemo
🧬 Neuroendocrine PCa treated as distinct entity
→ Less extrapolation, more precision
🔹 6. Supportive Care Matters
🦴 Bone-protective agents now standard with long-term ADT ± ARPI
→ Bone health is no longer optional
📌 What Changes ?
✅ re-label BCR risk groups
✅ stage smarter with PSMA-PET
✅ biopsy transperineally
✅ intensify systemic therapy
✅ embed bone health & MDT into routine care
Dr Bivek Kumar - Urologist
Fatih Bıçaklıoğlu retweeted
#EAU26 @ChrisSweens1: the field is reaching a consensus in mHSPC.
ADT + ARPI for nearly all patients, then personalize intensification:
• SBRT for low-volume
• Prostate RT in synchronous disease
• Docetaxel if high-volume and chemofit
🕒 The hope for the future: biomarkers to guide therapy, global access, and drug prices coming down so evidence-based care becomes feasible worldwide.
@uroweb @UroToday
Fatih Bıçaklıoğlu retweeted
#EAU26 ctDNA to guide adjuvant therapy after cystectomy?
•Conventional risk stratification may not be enough.
ctDNA positivity strongly predicts recurrence after RC
• Christensen et al: ctDNA+ → markedly higher relapse risk
• IMvigor010: benefit from adjuvant IO mainly in ctDNA+ pts
✅IMvigor011: ctDNA-guided atezolizumab improved DFS in ctDNA+ pts
@JBjerggaard: Yes, we are ready to guide adjuvant therapy with ctDNA!
@uroweb @UroToday
Fatih Bıçaklıoğlu retweeted
#EAU26 London – Take-Home Messages on Muscle-Invasive and Advanced Urothelial Cancer 🫵
Honoured to be part of the scientific committee office of the congress and to share today at the hashtag#EAU26 in London a short “Best of the Best” overview of the most impactful data shaping the management of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma.
Here are my key take-home messages:
1️⃣ Radical cystectomy remains central in MIBC (in 2026)
Despite the rapid development of systemic therapies and bladder-preserving strategies, radical cystectomy continues to be the cornerstone of curative treatment. Current diagnostic tools (imaging, endoscopy) still lack the accuracy needed to safely omit surgery in most patients.
2️⃣ Biomarkers are coming – but not ready to replace surgery
Circulating tumor DNA (ctDNA) is emerging as a powerful tool to identify minimal residual disease and systemic relapse risk. However, ctDNA currently reflects systemic disease rather than local bladder tumor burden. We are not yet able to confidently equate clinical complete response with pathological complete response.
3️⃣ EV + Pembrolizumab is reshaping the peri-operative landscape
Results from KEYNOTE-B15 / EV-304 and KEYNOTE-905 / EV-303 suggest that ADC + immune checkpoint inhibitor combinations may significantly improve outcomes compared with standard cisplatin-based chemotherapy.
But an essential message remains:
➡️ Systemic therapy must be integrated with radical cystectomy, not replace it.
4️⃣ In metastatic urothelial cancer: EV + Pembro is the new frontline standard
Data continue to confirm that enfortumab vedotin + pembrolizumab provides major improvements in PFS and OS versus platinum chemotherapy.
➡️ The paradigm has shifted: EVP first – ask questions later.
5️⃣ The next challenges
• Optimising toxicity management of EVP
• Identifying patients with early progression
• Integrating biomarkers and real-world evidence
• Defining the future role of chemotherapy in a rapidly evolving landscape
Exciting times in urothelial cancer, where surgery, systemic therapy, biomarkers and innovation are finally converging.
#EAU26 #BladderCancer #UrothelialCancer #MIBC #Oncology #Urology @Uroweb @AFUrologie
Fatih Bıçaklıoğlu retweeted
Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert
Fatih Bıçaklıoğlu retweeted
#EAU26 Does bladder preservation really improve QoL?
Dr. Gessner reviews the CISTO study (n=570) BST vs RC in recurrent high-grade NMIBC.
🔹 Physical function at 12 mo: similar between BST and RC
🔹 RC: better emotional function, ↓ anxiety/depression, ↓ financial burden
🔹 BST: better bowel & sexual outcomes
📊 Oncological outcomes:
• CSS similar (99% BST vs 96% RC)
• BST → higher recurrence rates
• RC → higher perioperative toxicity (90-day mortality ~2.5%)
@uroweb @UroToday
Fatih Bıçaklıoğlu retweeted
Thanks for the shoutout Tom.
We need to help our patients and deliver a unified message:
The OS advantage seen with EV+P
relies on consolidation with Radical
Cystectomy + PLND
(not observation, not TMT)
#EAU26
Fatih Bıçaklıoğlu retweeted
PRostate cancer guidelines 2026 update. Digital rectal exam NOW no more recommended for Asymptomatic men
SO NO MORE FOR Screening
Important for standing and for early diagnosis for SYMPTOMS only @Uroweb
Fatih Bıçaklıoğlu retweeted
Consider #Cystectomy in older population: better survival than TMT. Why not to perform Cystectomy and ureterocutaneostomy! Avoiding complications and #mortality in frail patients wit MI #bladdercancer . #EAU25. @FPuigvert.














































